{"url_path":"/sec/indp/8-k/2026-06-24/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-029918-index.html","accession_number":"0001493152-26-029918","cik":"0001857044","ticker":"INDP","issuer_name":"Indaptus Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-029918-index.html","primary_entity_key":"0001857044","primary_entity_name":"Indaptus Therapeutics, Inc."},"word_count":171,"has_tables":true,"body_markdown":"**Item\n3.02. Unregistered Sales of Equity Securities.**\n\n \n\nThe\ninformation set forth in Item 1.01 of this Current Report on Form 8-K concerning the offer and sale of the Common Stock to the Purchasers\npursuant to the Purchase Agreement is incorporated herein by reference.\n\n \n\nThe\nshares of Common Stock issued in connection with the Purchase Agreement were issued in reliance upon the exemptions from registration\nafforded by Section 4(a)(2) of the Securities Act and Regulation S promulgated thereunder. The Private Placement was conducted in offshore\ntransactions, as defined in Rule 902(h) of Regulation S, to persons who represented that they were not “U.S. persons,” as\ndefined in Rule 902(k) of Regulation S, and were not acquiring the shares for the account or benefit of any U.S. person. The Company\ndid not engage in any directed selling efforts, as defined in Rule 902(c) of Regulation S, in the United States in connection with the\nPrivate Placement. The shares of Common Stock are restricted securities as defined in Rule 144(a)(3) under the Securities Act."}